Основная статистика
| CIK | 1062822 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Lexicon Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 6, 2025 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 s |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon Ph |
|
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or orga |
|
| August 6, 2025 |
Calculation of Filing Fee Tables Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 Registration Statement (Form Type) Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registr |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2025 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organi |
|
| June 3, 2025 |
exh1012017equityincentiv Exhibit 10.1 LEXICON PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN This Plan initially was established as the Lexicon Genetics Incorporated 1995 Stock Option Plan (the “1995 Stock Option Plan”), which was adopted by the Board and approved by the Company’s stockholders on September 13, 1995. The 1995 Stock Option Plan was subsequently amended and restated in its entirety |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organi |
|
| June 3, 2025 |
2017 Non-Employee Directors’ Equity Incentive Plan exh1022017non-employeedi Exhibit 10.2 LEXICON PHARMACEUTICALS, INC. 2017 NON-EMPLOYEE DIRECTORS’ EQUITY INCENTIVE PLAN This Plan initially was established as the 2000 Non-Employee Directors’ Stock Option Plan, effective as of April 12, 2000 (the “2000 Non-Employee Directors’ Stock Option Plan”) which was adopted by the Board on February 3, 2000 and approved by the Company’s stockholders on March 1 |
|
| May 14, 2025 |
Exclusive License Agreement, dated March 27, 2025 Exhibit 10.1 [**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. EXCLUSIVE LICENSE AGREEMENT BETWEEN LEXICON PHARMACEUTICALS, INC. AND NOVO NORDISK A/S TABLE OF CONTENTS Page 1. DEFINITIONS 2. LICENSE GRANT; EXCLUSIVITY 2.1. Exclusive License to Novo Nordisk 2.2. Non-Exclusive License to Novo |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon P |
|
| May 13, 2025 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organi |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of th |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of th |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon Pharma |
|
| March 28, 2025 |
Seventh Amendment to Loan and Security Agreement Exhibit 10.1 [**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Seventh Amendment (this “Amendment”) to the Loan Agreement (as defined herein) is entered into as of March 27, 2025 (the “Seventh Amendment Date”), by and among OXFORD FINANC |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or orga |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of th |
|
| March 7, 2025 |
Exhibit 10.15 [**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT is dated and effective as of October 14, 2024, by and between LEXICON PHARMACEUTICALS, INC., a corporation incorporated under the laws of Delaware, USA, with its prin |
|
| March 7, 2025 |
Form of Stock Option Agreement with Officers Exhibit 10.11 STOCK OPTION AGREEMENT (Officer Stock Option) This Stock Option Agreement (this “Agreement”), effective as of (the “Grant Date”), is by and between Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Employee”). To carry out the purposes of the Company’s 2017 Equity Incentive Plan (the “Plan”) and the determination of the compensation committee (the “Compensa |
|
| March 7, 2025 |
Exhibit 10.1 [**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LEXICON PHARMACEUTICALS, INC. MANAGEMENT SEVERANCE PLAN ARTICLE I PURPOSE This Lexicon Pharmaceuticals, Inc. Management Severance Plan has been established by the Company on March 4, 2025 (the “Effective Date”) to provide Partic |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon Pharma |
|
| March 7, 2025 |
Insider Trading and Confidentiality Exhibit 19.1 Page 1 of 7 INSIDER TRADING AND CONFIDENTIALITY POLICY SECTION 1. PURPOSE The purpose of this Policy is to set forth the obligations and responsibilities of each director, officer and employee of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) with respect to Confidential Information and the prohibitions against insider trading. SECTION 2. DEFINITIONS 2.1. “Confidential Inf |
|
| March 7, 2025 |
Form of Restricted Stock Unit Agreement with Officers Exhibit 10.12 RESTRICTED STOCK UNIT AGREEMENT THIS RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”), effective as of (the “Grant Date”), is by and between Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Employee”). To carry out the purposes of the Company’s 2017 Equity Incentive Plan (the “Plan”) and the determination of the compensation committee (the “Compensation |
|
| March 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| March 6, 2025 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call and Webcast at 5:00 pm ET The Woodla |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2025 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or org |
|
| January 2, 2025 |
Exhibit 10.1 December 17, 2024 Scott Coiante Dear Scott: I extend this offer for you to join us as Senior Vice President and Chief Financial Officer at Lexicon Pharmaceuticals, Inc. (the “Company”), reporting to the Chief Executive Officer. This position will be located in our Bridgewater, NJ office. The terms under which we are offering you this position are outlined below: Start Date We expect t |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or org |
|
| December 9, 2024 |
SEVENTH AMENDED AND RESTATED JOINT FILING AGREEMENT EX-99.29 2 d882997dex9929.htm EX-99.29 Exhibit 29 SEVENTH AMENDED AND RESTATED JOINT FILING AGREEMENT This Seventh Amended and Restated Joint Filing Agreement (this “Agreement”) amends and restates the Sixth Amended and Restated Joint Filing Agreement, dated July 29, 2024. Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder ( |
|
| December 9, 2024 |
LXRX / Lexicon Pharmaceuticals, Inc. / Invus, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 24)* Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 528872302 (CUSIP Number) Anne Goffard Westend S.A. 44, Rue de la Vallée L-2661 Luxembourg Luxembourg (+352) 22.42.59-1 Copies |
|
| November 22, 2024 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2024 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
|
| November 20, 2024 |
Lexicon Appoints Ivan H. Cheung to Board of Directors Exhibit 99.1 Lexicon Appoints Ivan H. Cheung to Board of Directors THE WOODLANDS, Texas, November 20, 2024 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 528872302 (CUSIP Number) Sept |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexic |
|
| November 12, 2024 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 2024 Concluded Enrollment Screening For Phase 2b PROGRESS Study of LX9211 in Diabetic Peri |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or or |
|
| September 16, 2024 |
Consulting Agreement, dated September 13, 2024, with Jeffrey L. Wade Exhibit 10.2 September 13, 2024 Jeffrey L. Wade [Address] Dear Jeff: We are pleased to invite you to become a consultant to Lexicon Pharmaceuticals, Inc. (which, together with its subsidiaries and affiliates, is referred to as the “Company” or “Lexicon”). The purpose of this letter agreement (this “Agreement”) is to set forth our mutual understanding of the terms and conditions under which you wil |
|
| September 16, 2024 |
Separation Agreement, dated September 13, 2024, with Jeffrey L. Wade Exhibit 10.1 September 13, 2024 Jeffrey L. Wade [Address] Dear Jeff: The purpose of this letter is to confirm our agreement concerning your resignation as President and Chief Operating Officer of Lexicon Pharmaceuticals, Inc. (the “Company”). As of September 30, 2024 (the “Separation Date”), you hereby resign as President and Chief Operating Officer of the Company. In connection with such resignat |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2024 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or |
|
| August 9, 2024 |
[Letterhead of Lexicon Pharmaceuticals, Inc.] August 9, 2024 [Letterhead of Lexicon Pharmaceuticals, Inc.] August 9, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3561 Attention: Ms. Lauren Hamill Re: Lexicon Pharmaceuticals, Inc. Form S-3 Registration Statement Filed August 2, 2024 File No. 333-281208 Dear Ms. Hamill: Lexicon Pharmaceuticals, I |
|
| August 2, 2024 |
As filed with the Securities and Exchange Commission on August 2, 2024 Registration No. |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon Ph |
|
| August 2, 2024 |
Exhibit 4.10 LEXICON PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 , as Trustee TABLE OF CONTENTS Article 1. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions. 4 Section 1.3 Incorporation by Reference of Trust Indenture Act. 5 Section 1.4 Rules of Construction. 5 Article 2. THE SECURITIES 5 Section 2.1 Issuable in Series. 6 Section 2.2 Establis |
|
| August 2, 2024 |
Exhibit 107 Calculation of Filing Fees Table Form S-3 (Form Type) Lexicon Pharmaceuticals, Inc. |
|
| August 2, 2024 |
exh103officelease Research Forest Lakeside Building 4 Execution Copy OFFICE LEASE by and between RFL NO. |
|
| August 1, 2024 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE INPEFA® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study of Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) Expe |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or orga |
|
| July 29, 2024 |
LXRX / Lexicon Pharmaceuticals, Inc. / Invus, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 23)* Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 528872302 (CUSIP Number) Anne Goffard Westend S.A. 44, Rue de la Vallée L-2661 Luxembourg Luxembourg (+352) 22.42.59-1 Copies |
|
| July 29, 2024 |
SIXTH AMENDED AND RESTATED JOINT FILING AGREEMENT EX-99.28 Exhibit 28 SIXTH AMENDED AND RESTATED JOINT FILING AGREEMENT This Sixth Amended and Restated Joint Filing Agreement (this “Agreement”) amends and restates the Fifth Amended and Restated Joint Filing Agreement, dated January 21, 2021. Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersi |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organi |
|
| July 8, 2024 |
Offer Letter, dated July 3, 2024, with Michael Exton, Ph.D. Exhibit 10.1 July 2, 2024 Dr. Mike Exton [Address] Dear Mike: I extend this offer for you to join us as the Chief Executive Officer of Lexicon Pharmaceuticals, Inc. (the “Company”) with the backing and enthusiasm of the entire board of directors. We believe you have the right blend of leadership and personal and professional qualities to lead Lexicon in the next phase of its growth and development |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| July 1, 2024 |
Exhibit 10.1 [**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Sixth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of June 28, 2024, by and among OXFORD FINANCE LLC, a Delaware limited liability company wit |
|
| May 14, 2024 |
LXRX / Lexicon Pharmaceuticals, Inc. / Invus, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d839722dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 22)* Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 528872302 (CUSIP Number) Anne Goffard Westend S.A. 44, Rue de la Vallée L-2661 Luxembourg Luxem |
|
| May 13, 2024 |
Lexicon Pharmaceuticals, Inc. 2445 Technology Forest Blvd., 11th Floor The Woodlands, Texas 77381-1160 (281) 863-3000 May 13, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3561 Attention: Tyler Howes Re: Lexicon Pharmaceuticals, Inc. Form S-3 Registration Statement Filed March 25, 20 |
|
| May 10, 2024 |
Sixth Amended and Restated Certificate of Incorporation Exhibit 3.1 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LEXICON PHARMACEUTICALS, INC. LEXICON PHARMACEUTICALS, INC. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (“DGCL”), hereby certifies as follows pursuant to Sections 242 and 245 of the DGCL: FIRST: The name of the Corporation is “Lexicon Phar |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organi |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 10, 2024 Registration No. |
|
| May 2, 2024 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Commercial launch of INPEFA® (sotagliflozin) for Heart Failure continues to progress Resubmission of NDA for ZYNQUISTA™ (sotagliflozin) in Type 1 Diabetes expected mid-year 2024 Start-up ongoing for Phase 3 study of sotagliflozin in Hypertrophic Cardiomyopathy, with enrollment expected to |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organiz |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon P |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or orga |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of th |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of th |
|
| March 25, 2024 |
As filed with the Securities and Exchange Commission on March 25, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on March 25, 2024 Registration No. |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon Pharma |
|
| March 25, 2024 |
Summary of Non-Employee Director Compensation Exhibit 10.6 Summary of Non-Employee Director Compensation Each non-employee member of our Board of Directors shall receive the following cash compensation: •an annual retainer of $50,000 for service on the Board of Directors ($75,000 for service as non-executive Chairman of the Board of Directors), prorated for any partial year of service; •an annual retainer of $10,000 for service on the audit c |
|
| March 25, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lexicon Pharmaceuticals, Inc. |
|
| March 25, 2024 |
Incentive-Based Compensation Clawback Policy Exhibit 97.1 Lexicon Pharmaceuticals, Inc. Incentive-Based Compensation Clawback Policy (this “Policy”) Adopted by the Compensation Committee of the Board of Directors (the “Committee”) on October 26, 2023. 1. Recoupment. If Lexicon Pharmaceuticals, Inc. (the “Company”) is required to prepare a Restatement, the Committee shall, unless determined to be Impracticable, take reasonably prompt action t |
|
| March 25, 2024 |
Form of Restricted Stock Unit Agreement with Officers Exhibit 10.10 RESTRICTED STOCK UNIT AGREEMENT (Officer Restricted Stock Unit) This Restricted Stock Unit Agreement (this “Agreement”), effective as of (the “Grant Date”), is by and between Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Employee”). To carry out the purposes of the Company’s 2017 Equity Incentive Plan (the “Plan”) and the determination of the compensati |
|
| March 13, 2024 |
LXRX / Lexicon Pharmaceuticals, Inc. / Invus, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 21)* Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 528872302 (CUSIP Number) Anne Goffard Westend S.A. 44, Rue de la Vallée L-2661 Luxembourg Luxembourg (+352) 22.42.59-1 Copies |
|
| March 13, 2024 |
EX-99.27 2 d759789dex9927.htm EX-99.27 Exhibit 27 March 11, 2024 Invus, L.P. Invus Public Equities, L.P. Invus US Partners LLC c/o The Invus Group, LLC 750 Lexington Avenue, 30th Floor New York, New York 10022 Artal International S.C.A. 44 rue de la Vallée L-2661 Luxembourg Luxembourg Lexicon Pharmaceuticals, Inc. 2445 Technology Forest Blvd., 11th Floor The Woodlands, Texas 77381 Attn: President |
|
| March 12, 2024 |
Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK OF LEXICON PHARMACEUTICALS, INC. March 12, 2024 The undersigned, Brian T. Crum, Senior Vice President, General Counsel and Secretary of Lexicon Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), in accordance with the provisions of Section 151(g) of |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or orga |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| March 11, 2024 |
EX-99.1 Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Commercial launch of INPEFA® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase 2b study of LX9211 in Diabetic Peripheral Neu |
|
| March 11, 2024 |
Preferred Stock Purchase Agreement EX-10.1 Exhibit 10.1 PREFERRED STOCK PURCHASE AGREEMENT dated as of March 11, 2024 by and among LEXICON PHARMACEUTICALS, INC. and THE PURCHASERS PARTY HERETO TABLE OF CONTENTS Page ARTICLE I PURCHASE; CLOSING 1 Section 1.1 Purchase and Sale 1 Section 1.2 Closing 1 Section 1.3 Closing Conditions 2 Section 1.4 Deliveries 3 ARTICLE II REPRESENTATIONS AND WARRANTIES 4 Section 2.1 Representations and W |
|
| March 11, 2024 |
Amendment to Loan and Security Agreement EX-10.2 Exhibit 10.2 [**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Fifth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of March 6, 2024, by and among OXFORD FINANCE LLC, a Delaware limited liability com |
|
| March 11, 2024 |
LEXICON ANNOUNCES OVERSUBSCRIBED $250 MILLION PRIVATE PLACEMENT OF EQUITY SECURITIES EX-99.2 Exhibit 99.2 NEWS RELEASE FOR IMMEDIATE RELEASE LEXICON ANNOUNCES OVERSUBSCRIBED $250 MILLION PRIVATE PLACEMENT OF EQUITY SECURITIES The Woodlands, Texas, March 11, 2024 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a private investment in public equity financing that is expected |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of th |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 528872302 (CUSIP Number) Dece |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
|
| December 29, 2023 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM December 29, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s |
|
| December 29, 2023 |
Up to $75,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| December 29, 2023 |
Fourth Amendment to Loan and Security Agreement Exhibit 10.1 [**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Fourth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of December 29, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability compa |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or or |
|
| November 8, 2023 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Commercial launch of INPEFA® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology community Significant formulary inclusions effective in Q4 opening the opportunity for further com |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexic |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or org |
|
| August 4, 2023 |
As filed with the Securities and Exchange Commission on August 4, 2023 Registration No. |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon Ph |
|
| August 4, 2023 |
Calculation of Filing Fee Tables Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 Registration Statement (Form Type) Lexicon Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registr |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or orga |
|
| August 3, 2023 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE INPEFATM (sotagliflozin) receives FDA approval for the treatment of heart failure INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes LX9211 moving into late-stage development for the tre |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| July 31, 2023 |
Exhibit 99.1 LEXICON ELECTS DIANE E. SULLIVAN TO BOARD OF DIRECTORS Ms. Sullivan brings her extensive commercialization, strategy, and market access experience to the Lexicon Board of Directors The Woodlands, Texas, July 28, 2023 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Diane E. Sullivan has been elected to its Board of Directors. Ms. Sullivan brings extensive commercial |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| June 28, 2023 |
Amendment to Loan and Security Agreement Exhibit 10.1 [**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This Third Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of June 23, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability company wit |
|
| June 6, 2023 |
LXRX / Lexicon Pharmaceuticals Inc / Invus, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 20)* Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 528872302 (CUSIP Number) Anne Goffard Westend S.A. 44, Rue de la Vallée L-2661 Luxembourg Luxembourg (+352) 22.42.59-1 Copies |
|
| June 6, 2023 |
EX-99.27 Exhibit 27 LOCK-UP AGREEMENT May 31, 2023 Citigroup Global Markets Inc. Jefferies LLC Piper Sandler & Co. As Representatives of the several Underwriters c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Piper Sandler & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: The |
|
| June 2, 2023 |
EX-10.1 Exhibit 10.1 PURCHASE AGREEMENT May 31, 2023 Artal International S.C.A. 44 rue de la Vallée L-2661 Luxembourg Luxembourg Attention: Anne Goffard Lexicon Pharmaceuticals, Inc. 2445 Technology Forest Blvd., 11th Floor The Woodlands, Texas 77381 Attn: President and Chief Executive Officer Ladies and Gentlemen: Reference is made to (a) that certain Underwriting Agreement (the “Underwriting Agr |
|
| June 2, 2023 |
EX-1.1 Exhibit 1.1 LEXICON PHARMACEUTICALS, INC. 23,924,705 Shares Common Stock ($0.001 par value) Underwriting Agreement May 31, 2023 Citigroup Global Markets Inc. Jefferies LLC Piper Sandler & Co. As Representatives of the several Underwriters c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Piper Sa |
|
| June 2, 2023 |
LEXICON ANNOUNCES PRICING OF $125 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT EX-99.1 Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE LEXICON ANNOUNCES PRICING OF $125 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT The Woodlands, Texas, June 1, 2023 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 23,924,705 shares of its common stock, par value $0.001. The shares of |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organi |
|
| June 2, 2023 |
23,924,705 Shares Lexicon Pharmaceuticals, Inc. Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| June 1, 2023 |
LEXICON ANNOUNCES PRICING OF $125 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated June 1, 2023 Relating to Preliminary Prospectus Supplement dated May 31, 2023 Registration Statement No. |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organi |
|
| May 31, 2023 |
SUBJECT TO COMPLETION, DATED MAY 31, 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| May 31, 2023 |
LEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 31, 2023 Relating to Preliminary Prospectus Supplement dated May 31, 2023 Registration Statement No. |
|
| May 31, 2023 |
LEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK EX-99.1 Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE LEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK The Woodlands, Texas, May 31, 2023 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lex |
|
| May 8, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or or |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon P |
|
| May 2, 2023 |
Second Amendment to Loan and Security Agreement Exhibit 10.1 [**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Second Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of May 1, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability company wit |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organiz |
|
| May 2, 2023 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE NDA for Sotagliflozin on Track for May 27th, 2023 PDUFA date Conference Call and Webcast at 5:00 pm Eastern Time The Woodlands, Texas, May 2, 2023 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023 and provided an upd |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organiz |
|
| April 27, 2023 |
2017 Non-Employee Directors’ Equity Incentive Plan, as amended Exhibit 10.2 LEXICON PHARMACEUTICALS, INC. 2017 NON-EMPLOYEE DIRECTORS’ EQUITY INCENTIVE PLAN This Plan initially was established as the 2000 Non-Employee Directors’ Stock Option Plan, effective as of April 12, 2000 (the “2000 Non-Employee Directors’ Stock Option Plan”) which was adopted by the Board on February 3, 2000 and approved by the Company’s stockholders on March 15, 2000. The 2000 Non-Emp |
|
| April 27, 2023 |
Exhibit 10.1 LEXICON PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN This Plan initially was established as the Lexicon Genetics Incorporated 1995 Stock Option Plan (the “1995 Stock Option Plan”), which was adopted by the Board and approved by the Company’s stockholders on September 13, 1995. The 1995 Stock Option Plan was subsequently amended and restated in its entirety and renamed the Lexicon |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or orga |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of th |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of th |
|
| March 3, 2023 |
Form of Restricted Stock Unit Agreement Exhibit 10.10 RESTRICTED STOCK UNIT AGREEMENT (Officer Restricted Stock Unit) This Restricted Stock Unit Agreement (this “Agreement”), effective as of (the “Grant Date”), is by and between Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Employee”). To carry out the purposes of the Company’s 2017 Equity Incentive Plan (the “Plan”) and the determination of the compensati |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon Pharma |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| March 2, 2023 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE NDA for Sotagliflozin on Track for May 2023 PDUFA date following Late-Cycle Review Meeting LX9211 Demonstrates Consistent Results in Full Data from RELIEF-DPN-1 in Diabetic Peripheral Neuropathic Pain and Top-Line Data from RELIEF-PHN-1 in Post-Herpetic Neuralgia Conference Call and Webc |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 528872302 (CUSIP Number) Dece |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2022 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or or |
|
| November 9, 2022 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE NDA for Sotagliflozin Remains on Track for May 2023 PDUFA Date Following Mid-Cycle Review Meeting Final Data from Successful RELIEF-DPN-1 Study of LX9211 in Painful Diabetic Neuropathy to Be Presented at 16th Annual Pain Therapeutics Summit Next Week Conference Call and Webcast at 5:00 pm |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexic |
|
| September 2, 2022 |
First Amendment to Loan and Security Agreement Exhibit 10.1 [**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this ?Amendment?) is entered into as of August 29, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company w |
|
| September 2, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2022 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or org |
|
| August 9, 2022 |
LXRX / Lexicon Pharmaceuticals, Inc. / Invus, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 19)* Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 528872302 (CUSIP Number) Anne Goffard Westend S.A. 44, Rue de la Vall?e L-2661 Luxembourg Luxembourg (+352) 22.42.59-1 Copies to: Kenn |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon Ph |
|
| August 3, 2022 |
FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION LEXICON PHARMACEUTICALS, INC. EX-3.1 2 exh31-fifthamendedandresta.htm EX-3.1 Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LEXICON PHARMACEUTICALS, INC. LEXICON PHARMACEUTICALS, INC. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (“DGCL”), hereby certifies as follows pursuant to Sections 242 and 245 of the DGCL: FIRS |
|
| August 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or orga |
|
| August 2, 2022 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA, with PDUFA Action Date Anticipated in May 2023 LX9211 Phase 2 Clinical Proof-of-Concept Achieved in Painful Diabetic Neuropathy, Promising Novel Mechanism of Action in Neuropathic Pain Conference Call and We |
|
| August 1, 2022 |
Exhibit 25 LOCK-UP AGREEMENT July 26, 2022 Citigroup Global Markets Inc. Piper Sandler & Co. As Representatives of the several Underwriters c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Piper Sandler & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: The undersigned understands that Citigroup Global Markets Inc. (?Citigroup?) and Piper |
|
| August 1, 2022 |
LXRX / Lexicon Pharmaceuticals, Inc. / Invus, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d343806dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 18)* Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 528872302 (CUSIP Number) Anne Goffard Westend S.A. 44, Rue de la Vallée L-2661 Luxembourg Luxem |
|
| July 29, 2022 |
Exhibit 99.3 NEWS RELEASE FOR IMMEDIATE RELEASE LEXICON ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR SOTAGLIFLOZIN TO TREAT HEART FAILURE NDA supported by SOLOIST-WHF and SCORED Global Phase 3 Program Evaluating Sotagliflozin in Almost 12,000 People The Woodlands, Texas, July 27, 2022 ? Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration |
|
| July 29, 2022 |
LEXICON ANNOUNCES PRICING OF $85.0 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT Exhibit 99.2 NEWS RELEASE FOR IMMEDIATE RELEASE LEXICON ANNOUNCES PRICING OF $85.0 MILLION PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT The Woodlands, Texas, July 28, 2022 ? Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (?Lexicon?) today announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001 (the ?Common Stock?). |
|
| July 29, 2022 |
Exhibit 1.1 LEXICON PHARMACEUTICALS, INC. 16,843,600 Shares Common Stock ($0.001 par value) Underwriting Agreement July 27, 2022 Citigroup Global Markets Inc. Piper Sandler & Co. As Representatives of the several Underwriters c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Piper Sandler & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: L |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| July 29, 2022 |
16,843,600 Shares Common Stock 424B5 1 d258718d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258564 PROSPECTUS SUPPLEMENT (To Prospectus dated September 14, 2021) 16,843,600 Shares Common Stock We are selling an aggregate of 16,843,600 shares of our common stock at a purchase price equal to $2.50 per share. We have granted the underwriters an option to purchase up to 2,526,540 additiona |
|
| July 29, 2022 |
LEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE LEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK The Woodlands, Texas, July 27, 2022 ? Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (?Lexicon?) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001 (the ?Common Stock?). In |
|
| July 29, 2022 |
Exhibit 10.1 EXECUTION VERSION PURCHASE AGREEMENT July 27, 2022 Artal International S.C.A. 44 rue de la Vall?e L-2661 Luxembourg Luxembourg Attention: Anne Goffard The Invus Group, L.L.C. 750 Lexington Avenue (30th Floor) New York, New York 10022 Attention: David van Zandt Lexicon Pharmaceuticals, Inc. 2445 Technology Forest Blvd., 11th Floor The Woodlands, Texas 77381 Attn: President and Chief Ex |
|
| July 29, 2022 |
Exhibit 10.2 EXECUTION VERSION PURCHASE AGREEMENT July 27, 2022 Invus US Partners LLC 750 Lexington Avenue (30th Floor) New York, New York 10022 Attention: Philip J. Bafundo Lexicon Pharmaceuticals, Inc. 2445 Technology Forest Blvd., 11th Floor The Woodlands, Texas 77381 Attn: President and Chief Executive Officer Ladies and Gentlemen: Reference is made to (a) that certain Underwriting Agreement b |
|
| July 27, 2022 |
SUBJECT TO COMPLETION, DATED JULY 27, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258564 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permit |
|
| June 30, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| June 30, 2022 |
Exhibit 99.1 LEXICON ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT STUDY OF LX9211 IN PAINFUL DIABETIC NEUROPATHY Study Supports Translation of Potential New Mechanism of Action for Neuropathic Pain and Advancement of LX9211 Development in Painful Diabetic Neuropathy Conference Call and Webcast at 8:00 a.m. Eastern Time June 30, 2022 The Woodlands, Texas, June 29, 2022 - Lexico |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organi |
|
| May 25, 2022 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LEXICON PHARMACEUTICALS, INC. LEXICON PHARMACEUTICALS, INC. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (?DGCL?), hereby certifies as follows pursuant to Sections 242 and 245 of the DGCL: FIRST: The name of the Corporation is ?Lexicon Phar |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organiz |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon P |
|
| May 5, 2022 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE Conference Call and Webcast at 8:00 am Eastern Time The Woodlands, Texas, May 5, 2022 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2022 and provided an update on key milestones. ?We plan to resubmit our New Drug Appl |
|
| May 5, 2022 |
Exhibit 10.1 [**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this ?Agreement?) dated as of March 17, 2022 (the ?Effective Date?) among OXFORD FIN |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of th |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of th |
|
| March 17, 2022 |
Exhibit 99.1 LEXICON ENTERS INTO LOAN FACILITY WITH OXFORD FINANCE FOR UP TO $150 MILLION TO SUPPORT PLANNED COMMERCIALIZATION OF SOTAGLIFLOZIN The Woodlands, Texas, March 17, 2022 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it entered into a loan facility with Oxford Finance LLC that provides up to $150 million in borrowing capacity designed primarily to support commercial prep |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or orga |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of th |
|
| March 10, 2022 |
Form of Restricted Stock Unit Agreement with Officers Exhibit 10.10 RESTRICTED STOCK UNIT AGREEMENT (Officer Restricted Stock Unit) THIS RESTRICTED STOCK UNIT AGREEMENT (this ?Agreement?), effective as of (the ?Grant Date?), is by and between Lexicon Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and (?Employee?). To carry out the purposes of the Company?s 2017 Equity Incentive Plan (the ?Plan?) and the determination of the compensati |
|
| March 10, 2022 |
Exhibit 4.8 DESCRIPTION OF COMMON STOCK Authorized Common Stock We are authorized to issue up to 225 million shares of common stock, par value $0.001 per share. The following summary description of our common stock is based on the provisions of our second amended and restated certificate of incorporation, second amended and restated bylaws and the applicable provisions of the Delaware General Corp |
|
| March 10, 2022 |
Exhibit 10.3 [Lexicon Pharmaceuticals, Inc. Letterhead] July 26, 2021 Dr. Craig Granowitz, M.D., Ph.D. [Address] Dear Craig: Lexicon Pharmaceuticals, Inc. is pleased to offer you the position of Senior Vice President and Chief Medical Officer. The terms under which we are offering you this position are outlined below: Start Date We hope that you will begin employment on Monday, August 2, 2021. Sal |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon Pharma |
|
| March 10, 2022 |
Subsidiaries of Lexicon Pharmaceuticals, Inc. Exhibit 21.1 Subsidiaries of Lexicon Pharmaceuticals, Inc. The subsidiary of Lexicon Pharmaceuticals, Inc. set forth below does business under the name stated. Name of Subsidiary State of Incorporation or Formation Lexicon Pharmaceuticals (New Jersey), Inc. Delaware |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
|
| February 28, 2022 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE Conference Call and Webcast at 8:00 am Eastern Time The Woodlands, Texas, February 28, 2022 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today reported financial results for the three months and full-year ended December 31, 2021 and provided an update on key milestones. ? |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 528872302 (CUSIP Number) Dece |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexic |
|
| November 3, 2021 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE Conference Call and Webcast at 5:00 pm Eastern Time The Woodlands, Texas, November 3, 2021 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2021 and provided an update on key milestones. ?We are on track for submissi |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or or |
|
| September 10, 2021 |
[Letterhead of Lexicon Pharmaceuticals, Inc.] September 10, 2021 [Letterhead of Lexicon Pharmaceuticals, Inc.] September 10, 2021 Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Margaret Schwartz Re: Request for acceleration of effectiveness of registration statement on Form S?3 (File No. 333-258564) of Lexicon Pharmaceuticals, Inc. Ladies and Gentlemen: Pursuant to Rule 461 under the Sec |
|
| September 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2021 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
|
| August 6, 2021 |
Exhibit 4.12 DESCRIPTION OF COMMON STOCK Authorized Common Stock We are authorized to issue up to 225 million shares of common stock, par value $0.001 per share. The following summary description of our common stock is based on the provisions of our second amended and restated certificate of incorporation, second amended and restated bylaws and the applicable provisions of the Delaware General Cor |
|
| August 6, 2021 |
As filed with the Securities and Exchange Commission on August 6, 2021 Registration No. |
|
| August 6, 2021 |
As filed with the Securities and Exchange Commission on August 6, 2021 Registration No. |
|
| August 6, 2021 |
Exhibit 4.12 DESCRIPTION OF COMMON STOCK Authorized Common Stock We are authorized to issue up to 225 million shares of common stock, par value $0.001 per share. The following summary description of our common stock is based on the provisions of our second amended and restated certificate of incorporation, second amended and restated bylaws and the applicable provisions of the Delaware General Cor |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon Ph |
|
| August 6, 2021 |
Exhibit 4.14 LEXICON PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 , as Trustee TABLE OF CONTENTS Article 1. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions. 4 Section 1.3 Incorporation by Reference of Trust Indenture Act. 5 Section 1.4 Rules of Construction. 5 Article 2. THE SECURITIES 5 Section 2.1 Issuable in Series. 6 Section 2.2 Establis |
|
| August 2, 2021 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE Conference Call and Webcast at 8:00 am Eastern Time The Woodlands, Texas, July 30, 2021 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2021 and provided an update on key milestones. ?We remain on track to submit our New |
|
| August 2, 2021 |
Exhibit 99.2 Event Name: [ LXRX ] - Lexicon Pharmaceuticals, Inc. Second Quarter 2021 Financial Results Conference Call Event Date: Friday, July 30, 2021, 8:00 AM Eastern Time Officers and Speakers Charles Schultz; Corporate Communications Lonnel Coats; President and Chief Executive Officer Jeffrey Wade; EVP of Corporate and Administrative Affairs and Chief Financial Officer Analysts Yigal Nochomo |
|
| August 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2021 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| July 30, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2021 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| July 30, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2021 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organ |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or organiz |
|
| May 6, 2021 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE Conference Call and Webcast at 5:00 pm Eastern Time The Woodlands, Texas, May 6, 2021 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2021 and provided an update on key milestones. ?We continue to enroll patients in our |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon P |
|
| May 3, 2021 |
Second Amended and Restated Certificate of Incorporation EX-3.1 2 exh31-secondamendedandrest.htm EX-3.1 Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LEXICON PHARMACEUTICALS, INC. LEXICON PHARMACEUTICALS, INC. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (“DGCL”), hereby certifies as follows pursuant to Sections 242 and 245 of the DGCL: FIR |
|
| May 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or orga |
|
| May 3, 2021 |
2017 Non-Employee Directors’ Equity Incentive Plan Exhibit 10.1 LEXICON PHARMACEUTICALS, INC. 2017 NON-EMPLOYEE DIRECTORS? EQUITY INCENTIVE PLAN This Plan initially was established as the 2000 Non-Employee Directors? Stock Option Plan, effective as of April 12, 2000 (the ?2000 Non-Employee Directors? Stock Option Plan?) which was adopted by the Board on February 3, 2000 and approved by the Company?s stockholders on March 15, 2000. The 2000 Non-Emp |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or orga |
|
| March 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of th |
|
| March 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of th |
|
| March 12, 2021 |
Exhibit 4.11 DESCRIPTION OF COMMON STOCK Authorized Common Stock We are authorized to issue up to 225 million shares of common stock, par value $0.001 per share. The following summary description of our common stock is based on the provisions of our amended and restated certificate of incorporation, as amended, second amended and restated bylaws and the applicable provisions of the Delaware Genera |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexicon Pharma |
|
| March 12, 2021 |
Release and Severance Agreement Exhibit 10.5 RELEASE AND SEVERANCE AGREEMENT This Release and Severance Agreement (?Agreement?) is being entered into by the individual executing this Agreement below (?Employee?) and Lexicon Pharmaceuticals Inc. (?Employer?) (collectively, the ?Parties?) in order to further the mutually desired terms and conditions set forth herein: 1.Severance Payment. For and in consideration for Employee?s exe |
|
| March 12, 2021 |
Release and Severance Agreement Exhibit 10.6 RELEASE AND SEVERANCE AGREEMENT This Release and Severance Agreement (?Agreement?) is being entered into by the individual executing this Agreement below (?Employee?) and Lexicon Pharmaceuticals Inc. (?Employer?) (collectively, the ?Parties?) in order to further the mutually desired terms and conditions set forth herein: 1.Severance Payment. For and in consideration for Employee?s exe |
|
| March 10, 2021 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2020 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE Conference Call and Webcast at 5:00 pm Eastern Time The Woodlands, Texas, March 10, 2021 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2020 and provided an update on key milestones. “Du |
|
| March 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or orga |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of th |
|
| February 12, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2021 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or or |
|
| February 12, 2021 |
Exhibit 10.1 SUBLEASE AGREEMENT This Sublease Agreement (this ?Sublease?) is entered into as of February 8, 2021 (the ?Effective Date?), by and between Repsol Oil & Gas USA, LLC, a Texas limited liability company (?Sublandlord?), and Lexicon Pharmaceuticals, Inc., a Delaware corporation (?Subtenant?). RECITALS: A. RFL No. 4 Limited Partnership (successor-in-interest to JD Warmack Woodlands Limited |
|
| January 21, 2021 |
Amendment No. 17 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 17)* Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 528872302 (CUSIP Number) Anne Goffard Westend S.A. 44, Rue de la Vallée L-2661 Luxembourg Luxembourg |
|
| January 21, 2021 |
FIFTH AMENDED AND RESTATED JOINT FILING AGREEMENT Exhibit 22 EXHIBIT 22 FIFTH AMENDED AND RESTATED JOINT FILING AGREEMENT This Fifth Amended and Restated Joint Filing Agreement (this “Agreement”) amends and restates the Fourth Amended and Restated Joint Filing Agreement, dated January 5, 2021, by and among Invus, L. |
|
| January 14, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or or |
|
| January 14, 2021 |
LEXICON PHARMACEUTICALS PROVIDES REGULATORY UPDATE ON SOTAGLIFLOZIN IN HEART FAILURE EX-99.1 7 regulatoryupdateonsotaglif.htm EX-99.1 Exhibit 99.1 LEXICON PHARMACEUTICALS PROVIDES REGULATORY UPDATE ON SOTAGLIFLOZIN IN HEART FAILURE The Woodlands, Texas, January 14, 2021 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies ca |
|
| January 5, 2021 |
Amendment No. 16 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 16)* Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 528872302 (CUSIP Number) Anne Goffard Westend S.A. 44, Rue De La Vallée L-2661 Luxembourg Luxembourg |
|
| January 5, 2021 |
Exhibit 21 EXHIBIT 21 POWER OF ATTORNEY Know all men by these presents that Pascal Minne (the “Undersigned”) does hereby make, constitute and appoint Anne Goffard or alternatively Pierre Claudel as a true and lawful attorney-in-fact of the Undersigned with full powers of substitution, for and in the name, place and stead of the Undersigned both in: 1) the Undersigned’s individual capacity, and 2) |
|
| January 5, 2021 |
FOURTH AMENDED AND RESTATED JOINT FILING AGREEMENT Exhibit 20 EXHIBIT 20 FOURTH AMENDED AND RESTATED JOINT FILING AGREEMENT This Fourth Amended and Restated Joint Filing Agreement (this “Agreement”) amends and restates the Third Amended and Restated Joint Filing Agreement, dated December 16, 2020, by and among Invus, L. |
|
| December 21, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated December 21, 2020 with respect to the shares of Common Stock, par value $0.001, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Sec |
|
| December 21, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| December 18, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
|
| December 18, 2020 |
Supplement No. 3 to the Transaction Agreements EX-10.1 Exhibit 10.1 Execution Version SUPPLEMENT NO. 3 TO TRANSACTION AGREEMENTS This Supplement No. 3 to Transaction Agreements (this “Supplement”) is entered into as of December 16, 2020 by and among Invus, L.P., a Bermuda limited partnership (“Invus, L.P.”), Invus C.V., a Netherlands limited partnership (“Invus C.V.”), and Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”). |
|
| December 16, 2020 |
Amendment No. 15 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 15)* Lexicon Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 528872302 (CUSIP Number) Anne Goffard Westend S.A. 44, Rue De La Vallée L-2661 Luxembourg Luxembourg |
|
| December 16, 2020 |
THIRD AMENDED AND RESTATED JOINT FILING AGREEMENT Exhibit 18 EXHIBIT 18 THIRD AMENDED AND RESTATED JOINT FILING AGREEMENT This Third Amended and Restated Joint Filing Agreement (this “Agreement”) amends and restates the Amended and Restated Joint Filing Agreement, dated April 10, 2012, by and among Invus, L. |
|
| December 11, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
|
| December 11, 2020 |
EX-10.2 Exhibit 10.2 Execution Version 20,312,500 SHARES OF COMMON STOCK PLACEMENT AGENCY AGREEMENT December 11, 2020 Citigroup Global Markets Inc. 388 Greenwich St. New York, New York 10013 Ladies and Gentlemen: Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions of this Placement Agency Agreement (the “Agreement”) and the Purchase |
|
| December 11, 2020 |
EX-99.1 Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE LEXICON PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR LX9211 FOR DIABETIC PERIPHERAL NEUROPATHIC PAIN The Woodlands, Texas, December 11, 2020 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of LX9 |
|
| December 11, 2020 |
20,312,500 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-234568 PROSPECTUS SUPPLEMENT (To Prospectus dated November 18, 2019) 20,312,500 Shares Common Stock We are offering an aggregate of 20,312,500 shares of our common stock to certain institutional and accredited investors at a purchase price equal to $3.20 per share. Artal International S.C.A. (“Artal”), an affiliate of In |
|
| December 11, 2020 |
EX-10.1 Exhibit 10.1 Execution Version SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is dated as of December 11, 2020 (the “Effective Date”), among Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Artal International S.C.A. (the “Invus Purchasers”) and each other purchaser identified on the signature pages hereto (each a “Purchaser” and collectively wi |
|
| December 11, 2020 |
Risks related to regulatory approval of our drug candidates EX-99.3 EXHIBIT 99.3 Risks related to regulatory approval of our drug candidates We depend on our ability to gain alignment with the FDA and other regulatory authorities on our regulatory strategy for sotagliflozin in heart failure. If we fail to effectively gain such alignment, our business will suffer and our stock price will likely decline. We have reported positive results from two outcomes st |
|
| December 11, 2020 |
EX-99.2 EXHIBIT 99.2 Overview We are a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. We are devoting most of our resources to the research and development of our most advanced drug candidates: • We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. We identified the target of LX9211, adap |
|
| December 11, 2020 |
LEXICON ANNOUNCES OFFERING OF COMMON STOCK EX-99.1 Exhibit 99.1 LEXICON ANNOUNCES OFFERING OF COMMON STOCK The Woodlands, Texas, December 11, 2020 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it had entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale, in a registered direct offering, of 20,312,500 shares of its common stock, par value $0.001 (the “Comm |
|
| December 11, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2020 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
|
| November 17, 2020 |
Exhibit 99.1 RESULTS FROM SOLOIST AND SCORED OUTCOMES STUDIES PRESENTED AT LATE-BREAKING SCIENCE SESSION OF AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies The Woodlands, Texas, November 16, |
|
| November 17, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
|
| October 30, 2020 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-234568 PROSPECTUS SUPPLEMENT (To Prospectus dated November 18, 2019) Up to $50,000,000 Common Stock We have entered into an Open Market Sale AgreementSM (the “sales agreement”) with Jefferies LLC (“Jefferies”) relating to the shares of our common stock, par value $0.001 per share (“common stock”), offered by this prospectus supplement. In accor |
|
| October 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 000-30111 Lexic |
|
| October 30, 2020 |
, dated October 30, 2020, with Jefferies LLC Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM1 October 30, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Lexicon Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s |
|
| October 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or or |
|
| October 29, 2020 |
Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE Conference Call and Webcast at 8:00 am Eastern Time The Woodlands, Texas, October 29, 2020 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2020 and provided an update of key milestones. “In the third quarter, we str |
|
| October 22, 2020 |
REAL ESTATE PURCHASE AND SALE AGREEMENT BETWEEN LEX-GEN WOODLANDS, L.P. AND Nurix Therapeutics, Inc. CONCERNING PROPERTY COMMONLY KNOWN AS 8800 TECHNOLOGY FOREST PLACE IN THE WOODLANDS, TEXAS TABLE OF CONTENTS PAGE ARTICLE 1 Definitions 1 Section 1.1 Definitions 1 ARTICLE 2 Agreement; Purchase Price 5 Section 2.1 Agreement to Sell and Purchase 5 Section 2.2 Purchase Price 6 Section 2.3 Leaseback t |
|
| October 22, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2020 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or or |
|
| September 29, 2020 |
Unregistered Sales of Equity Securities - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2020 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or |
|
| September 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2020 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or |
|
| September 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2020 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
|
| September 11, 2020 |
Exhibit 99.1 LEXICON PHARMACEUTICALS COMPLETES THE SALE OF XERMELO TO TERSERA THERAPEUTICS Lexicon Receives $160.4 Million at Closing Eligible for Up to $65 Million in Milestone Payments Plus Mid-Teens Royalties on Net Sales of XERMELO in Biliary Tract Cancer Substantial Debt Reduction with Full Repayment of Secured Loan The Woodlands, Texas, September 8, 2020 – Lexicon Pharmaceuticals, Inc. (Nasd |
|
| September 11, 2020 |
Exhibit 99.2 LEXICON PHARMACEUTICALS, INC. UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET AND CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) The unaudited consolidated pro forma financial information should be read in conjunction with the Current Report on Form 8-K of Lexicon Pharmaceuticals, Inc. (the "Company") filed with the Securities and Exchange Commission on September 11, 2020, reportin |
|
| September 11, 2020 |
Asset Purchase and Sale Agreement Exhibit 2.1 [**] Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. ASSET PURCHASE AND SALE AGREEMENT BY AND BETWEEN LEXICON PHARMACEUTICALS, INC. a Delaware corporation and TERSERA THERAPEUTICS LLC a Delaware limited liability company July 29, 2020 TABLE OF CONTENTS Page Article I PURCHASE AND S |
|
| September 11, 2020 |
, 2020, by and between Lexicon Pharmaceuticals, Inc. and TerSera Therapeutics LLC Exhibit 2.2 FIRST AMENDMENT TO ASSET PURCHASE AND SALE AGREEMENT This First Amendment to Asset Purchase and Sale Agreement (this “Amendment”), dated as of August 10, 2020, is entered into by and between Lexicon Pharmaceuticals, Inc., a Delaware corporation (“Seller”), and TerSera Therapeutics LLC, a Delaware limited liability company (“Buyer”). Capitalized terms used but not otherwise defined here |
|
| September 8, 2020 |
Termination of a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2020 Lexicon Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 000-30111 76-0474169 (State or other jurisdiction of incorporation or o |
